Literature DB >> 25976683

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

John Hutchinson1, Andrew Fogarty2, Richard Hubbard2, Tricia McKeever2.   

Abstract

As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a need to coordinate data on incidence and mortality globally. This study aims to systematically assess all available studies to investigate the global burden of disease.Medline and Embase databases were searched systematically for all population-based studies of incidence or mortality of idiopathic pulmonary fibrosis. Clinical case series and prevalence studies were excluded. The search was supplemented using the Google search engine, hand-searching of references and conference abstracts. Data were extracted independently by two authors using a pre-specified proforma, with assessment of methodological quality.34 studies were identified, providing data from 21 countries from 1968-2012. 28 studies reported incidence data and eight reported mortality data. In studies from the year 2000 onwards, we estimated a conservative incidence range of 3-9 cases per 100 000 per year for Europe and North America. Incidence was lower in East Asia and South America. The majority of studies showed an increase in incidence over time.The incidence of idiopathic pulmonary fibrosis is increasing worldwide and rates are coming together across countries. Current data suggest incidence is similar to that of conditions such as stomach, liver, testicular and cervical cancers.
Copyright ©ERS 2015.

Entities:  

Mesh:

Year:  2015        PMID: 25976683     DOI: 10.1183/09031936.00185114

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  215 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?

Authors:  Christopher L Mosher; Robert J Mentz
Journal:  Am Heart J       Date:  2020-05-06       Impact factor: 4.749

Review 3.  Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.

Authors:  Justin C Hewlett; Jonathan A Kropski; Timothy S Blackwell
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

4.  Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis.

Authors:  Franco Conforti; Robert Ridley; Christopher Brereton; Aiman Alzetani; Benjamin Johnson; Ben G Marshall; Sophie V Fletcher; Christian H Ottensmeier; Luca Richeldi; Paul Skipp; Yihua Wang; Mark G Jones; Donna E Davies
Journal:  Cell Death Discov       Date:  2020-06-30

5.  Fibroblast growth factor 2 induces proliferation and fibrosis via SNAI1-mediated activation of CDK2 and ZEB1 in corneal endothelium.

Authors:  Jeong Goo Lee; Eric Jung; Martin Heur
Journal:  J Biol Chem       Date:  2018-01-23       Impact factor: 5.157

6.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Authors:  Olga B Garbuzenko; Vera Ivanova; Vladislav Kholodovych; David C Reimer; Kenneth R Reuhl; Edvard Yurkow; Derek Adler; Tamara Minko
Journal:  Nanomedicine       Date:  2017-04-19       Impact factor: 5.307

8.  The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.

Authors:  Bintou A Ahidjo; Mariama C Maiga; Elizabeth A Ihms; Mamoudou Maiga; Alvaro A Ordonez; Laurene S Cheung; Sarah Beck; Bruno B Andrade; Sanjay Jain; William R Bishai
Journal:  JCI Insight       Date:  2016-09-08

9.  HDAC8 inhibition ameliorates pulmonary fibrosis.

Authors:  Shigeki Saito; Yan Zhuang; Takayoshi Suzuki; Yosuke Ota; Marjorie E Bateman; Ala L Alkhatib; Gilbert F Morris; Joseph A Lasky
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-25       Impact factor: 5.464

10.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.